Posted by Michael Wonder on 15 Oct 2019
Akorn receives FDA approval for betamethasone dipropionate 0.05% lotion USP (augmented)
14 October 2019 - Akorn today announced that it received a new abbreviated new drug application approval from the U.S. FDA for betamethasone dipropionate lotion USP (augmented), 0.05%.
The product is manufactured at Akorn’s Amityville, New York manufacturing facility.
According to IQVIA, U.S. sales of betamethasone dipropionate lotion (augmented), 0.05% were approximately $10 million for the twelve months ended August 2019.
